Digital health technology has the potential to transform cancer care
ASCO serves up shock as Roche’s data disappoints
Kite, Juno, and BlueBird will give updates on T-cell therapies.
Immunotherapy combinations will be the focus – but attention is shifting towards these agents proving their overall survival benefits.
Pharma needs to remedy its approach to digital conference engagement.
An overview of the latest on immunotherapies, progress in multiple myeloma and benefits of patient-reported outcomes.